References
Ahles, T. A., & Saykin, A. J. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigation, 19, 812-820. doi: 10.1081/CNV-100107743
Ahles, T. A., & Saykin, A. J. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nature Reviews Cancer, 7, 192-201. doi: 10.1038/nrc2073
Ahles, T. A., Saykin, A. J., Furstenberg, C. T., Cole, B., Mott, L. A., Skalla, K., … Siberfarb, P. M. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.
American Cancer Society. (2010). Cancer facts and figures, 2010. Atlanta, GA: Author.
Barnes, D. E., Cauley, J. A., Lui, L. Y., Fink, H. A., McCulloch, C., Stone, K. L., & Yaffe, K. (2007). Women who maintain optimal cognitive function into old age. Journal of the American Geriatric Society, 55, 259-264. doi: 10.1111/j.1532-5415.2007.01040.x
Beck, S., Dudley, W. N., & Barsevick, A. M. (2005). Pain, sleep disturbance, and fatigue in patients with cancer: Using a mediation model to test a symptom cluster [Online exclusive]. Oncology Nursing Forum, 32, E48-E55. doi: 10.1188/05.ONF.E48-E55
Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K., & Ryan, C. M. (2006). Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 15, 422-430. doi: 10.1002/pon.964
Bender, C. M., Sereika, S. M., Brufsky, A. M., Ryan, C. M., Vogel, V. G., Rastorgi, P., … Berga, S. L. (2007). Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause, 14, 995-998. doi: 10.1097/gme.0b013e318148b28b
Brezden, C. B., Phillips, K. A., Abdolell, M., Bunston, T., & Tannock, I. F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 4175-4183.
Castellon, S. A., Ganz, P. A., Bower, J. E., Peterson, L., Abraham, L., & Greendale, G. A. (2004). Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology, 26, 955-969. doi: 10.1080/13803390490510905
Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St. Clair, D. K. (2007). Collateral damage in cancer chemotherapy: Oxidative stress in nontargeted tissues. Molecular Interventions, 7, 147-155. doi: 10.1124/mi.7.3.6
Cimprich, B., So, H., Ronis, D. L., & Trask, C. (2005). Pretreatment factors related to cognitive functioning in women newly diagnosed with breast cancer. Psycho-Oncology, 14, 70-78. doi: 10.1002/pon.821
Cleeland, C. S., Mendoza, T. R., Wang, X. S., Chou, C., Harle, M. T., Morrissey, M., & Engstrom, M. C. (2000). Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory. Cancer, 89, 1634-1646.
Cohen, J. (1992). A power primer. Psychological Bulletin, 112, 155-159.
Daffner, K. R., Ryan, K. K., Williams, D. M., Budson, A. E., Rentz, D. M., Wolk, D. A., & Holcomb, P. J. (2006). Increased responsiveness to novelty is associated with successful cognitive aging. Journal of Cognitive Neuroscience, 18, 1759-1773. doi: 10.1162/jocn.2006.18.10.1759
Donovan, H. S., Ward, S., Sherwood, P., & Serlin, R. (2008). Evaluation of the Symptom Representation Questionnaire (SRQ) for assessing cancer-related symptoms. Journal of Pain and Symptom Management, 35, 242-257. doi: 10.1016/j.jpainsymman.2007.04.017
Ferguson, R. J., McDonald, B. C., Saykin, A. J., & Ahles, T. A. (2007). Brain structure and function differences in monozygotic twins: Possible effects of breast cancer chemotherapy. Journal of Clinical Oncology, 25, 3866-3870. doi: 10.1200/JCO.2007.10.8639
Fleishman, S. B. (2004). Treatment of symptom clusters: Pain, depression, and fatigue. Journal of the National Cancer Institute. Monographs, 32, 119-123. doi: 10.1093/jncimonographs/lgh028
Hart, R. P., Wade, J. B., & Martelli, M. F. (2003). Cognitive impairment in patients with chronic pain: The significance of stress. Current Pain and Headache Reports, 7, 116-126. doi: 10.1007/s11916-003-0021-5
Hess, L. M., & Insel, K. C. (2007). Chemotherapy-related change in cognitive function: A conceptual model. Oncology Nursing Forum, 24, 981-994. doi: 10.1188/07.ONF.981-994
Hillman, C. H., Moti, R. W., Pontifex, M. B., Posthuma, D., Stubbe, J. H., Boomsma, D. I., & de Geus, E. J. (2006). Physical activity and cognitive function in a cross-section of younger and older community-dwelling individuals. Health Psychology, 25, 678-687.
Jacobs, S. R., Jacobsen, P. B., Booth-Jones, M., Wagner, L. I., & Anasetti, C. (2007). Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. Journal of Pain and Symptom Management, 33, 13-23.
Jenkins, V., Shilling, V., Deutsch, G., Bloomfield, D., Allan, S., Bishop, H., … Winstanley, J. (2006). A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 94, 828-834.
Jenkins, V., Shilling, V., Fallowfield, L., Howell, A., & Hutton, S. (2004). Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology, 13, 61-66. doi: 10.1002/pon.709
Klemp, J. R., Stanton, A. L., Kimler, B. F., & Fabian, C. J. (2006). Evaluating the effects of chemotherapy on cognitive function and quality of life in premenopausal women with breast cancer. Paper presented at the San Antonio Breast Cancer Symposium, San Antonio, TX.
Kreukels, B. P., Schagen, S. B., Ridderinkhof, K. R., Boogerd, W., Hamburger, H. L., Muller, M. J., & van Dam, F. S. (2006). Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: An electrophysiologic study. Clinical Breast Cancer, 7, 67-78. doi: 10.3816/CBC.2006.n.015
Lee, B., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., … Cleeland, C. S. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11, 279-282. doi: 10.1159/000079408
Lenz, E. R., Pugh, L. C., Milligan, R. A., Gift, A. G., & Suppe, F. (1997). The middle-range theory of unpleasant symptoms: An update. Advances in Nursing Science, 19(3), 14-27.
Lenz, E. R., Suppe, F., Gift, A. G., Pugh, L. C., & Milligan, R. A. (1995). Collaborative development of middle-range nursing theories: Toward a theory of unpleasant symptoms. Advances in Nursing Science, 17(3), 1-13.
Malmstrom, H., & Karlsson, T. (2003). Cognitive functions in patients with ovarian cancer receiving chemotherapy [Abstract 1855]. Proceedings of the American Society of Clinical Oncologists, 22, 462.
Myers, J. S. (2009). A comparison of the theory of unpleasant symptoms and the conceptual model of chemotherapy-related changes in cognitive function [Online exclusive]. Oncology Nursing Forum, 12, E1-E10. doi: 10.1188/09.ONF.E1-E10
O'Shaughnessy, J. (2003). Chemotherapy-related cognitive dysfunction in breast cancer. Seminars in Oncology Nursing, 19(Suppl. 2), 17-24.
Schagen, S. B., Muller, M. J., Boogerd, W., & van Dam, F. S. (2002). Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clinical Breast Cancer, 3(Suppl. 3), S100-S1008. doi: 10.3816/CBC.2002.s.020
Schagen, S. B., van Dam, F. S., Muller, M. J., Boogerd, W., Lindeboom, J., & Bruning, P. F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.
Tchen, N., Juffs, H. G., Downie, F. P., Yi, Q. L., Hu, H., Chemerynsky, I., & Tannock, I. F. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.
Tortolero-Luna, G., & Mitchell, M. F. (2004). The epidemiology of ovarian cancer. Journal of Cellular Biochemistry, 59(S23), 200-207.
Troy, L., McFarland, K., Littman-Power, S., Kelly, B. J., Walpole, E. T., Wyld, D., & Thomson, D. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncology, 9, 29-39.
van Dam, F. S., Schagen, S. B., Muller, M. J., Boogerd, W., Wall, E., Droogleever Fortuyn, M. E., & Rodenhuis, S. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.
Wieneke, M. H., & Dienst, E. R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66. doi: 10.1002/pon.2960040108
Wood, L. J., Nail, L. M., Perrin, N. A., Elsea, C. R., Fischer, A., & Druker, B. J. (2006). The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biological Research for Nursing, 8, 157-169.
Yaffe, K., Barnes, D. E., Lindquist, K., Cauley, J. A., Simonsick, E. M., Penninx, B., … Health ABC Investigators. (2007). Endogenous sex hormone levels and risk of cognitive decline in an older biracial cohort. Neurobiology of Aging, 28, 171-178.